SCHEMBL3087740

SCHEMBL3087740

CC(C)N(C(=O)C(Cc1ccc(C#N)cc1)C(=O)NS(=O)(=O)c1ccc2ccccc2c1)c1ccc(F)cc1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LARS1 Q9P2J5 1/20 0.44
CNR1 P21554 1/20 0.43
CNR2 P34972 1/20 0.43
KAT6A Q92794 8/20 0.43
F2 P00734 3/20 0.43
SIRT2 Q8IXJ6 1/20 0.39
NLRP3 Q96P20 1/20 0.38
CTSS P25774 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
RORC P51449 2/20 0.37
KAT7 O95251 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
KCNH2 Q12809 1/20 0.37
KAT6B Q8WYB5 1/20 0.37
KAT5 Q92993 1/20 0.37
KAT8 Q9H7Z6 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3092646 0.92 KAT6A (0.46) LARS1CNR1CNR2KAT6AF2
SCHEMBL3101068 0.89 LARS1 (0.46) LARS1CNR1CNR2KAT6AF2
SCHEMBL3102827 0.86 MEN1 (0.50) LARS1KAT6AF2NLRP3MEN1
SCHEMBL3080156 0.85 USP30 (0.49) LARS1KAT6AF2MEN1KMT2A
SCHEMBL3096954 0.84 LARS1 (0.45) LARS1KAT6AF2NLRP3MEN1
SCHEMBL14999890 0.83 LARS1 (0.47) LARS1CNR1CNR2KAT6AF2
SCHEMBL3097728 0.83 LARS1 (0.59) LARS1KAT6AF2NLRP3MEN1
SCHEMBL3085443 0.82 PPARG (0.49) LARS1KAT6AF2MEN1KMT2A
SCHEMBL3093550 0.82 LARS1 (0.44) LARS1CNR1CNR2KAT6AF2
SCHEMBL3089218 0.81 KAT6A (0.51) LARS1CNR1CNR2KAT6AF2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2172450-B9 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2014-10-08 EP disclosed
EP-2172450-B1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2013-10-16 EP disclosed
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed
EP-2172450-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2010-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 LARS1 1976/4885CNR1 1167/4885CNR2 907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.